论文部分内容阅读
目的:探讨中重度内异症患者术后辅助不同药物治疗的生存质量。方法:将96例中重度内异症患者随机分成A、B两组,A组(47例)术后辅助促性腺激素释放激素激动剂(GnRHa)治疗,B组(49例)术后辅助孕三烯酮治疗,对每组患者进行术前1周、术后1月、3月、6月的随访并行生存质量评分,分析两组的生存质量。结果:A、B两组患者的缓解率、复发率差异无统计学意义;A组患者副反应发生率高于B组(P<0.05),B组患者术后3月、6月生存质量明显高于A组患者。结论:术后辅助GnRHa和孕三烯酮治疗中重度内异症其短期疗效(缓解率和复发率)无明显差异,对生存质量的改善后者优于前者。
Objective: To investigate the quality of life of patients with moderate-severe endometriosis after adjuvant treatment with different drugs. Methods: Ninety-six patients with moderate-severe endometriosis were randomly divided into two groups: group A (n = 47) and postoperative adjuvant gonadotropin-releasing hormone agonist (group GnRHa) Three enkephalin treatment, each group of patients were followed up for 1 week, 1 month, 3 months and 6 months after operation, and the quality of life was analyzed. Results: There was no significant difference in remission rate and recurrence between group A and group B. The incidence of side reaction in group A was higher than that in group B (P <0.05), and the quality of life in group B was significantly higher at 3 and 6 months Higher than the A group of patients. CONCLUSION: There is no significant difference in short-term efficacy (remission rate and recurrence rate) between postoperative adjuvant GnRHa and gestrinone in the treatment of moderate to severe endometriosis. The improvement of quality of life is better than the former.